Harmony Biosciences Holdings (HRMY)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 173,396 | 104,686 | 37,428 | -41,380 |
| Revenue | US$ in thousands | 548,499 | 419,060 | 255,101 | 134,691 |
| Pretax margin | 31.61% | 24.98% | 14.67% | -30.72% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $173,396K ÷ $548,499K
= 31.61%
The pretax margin of Harmony Biosciences Holdings Inc has shown a positive trend over the past four years, increasing from -23.13% in 2020 to 29.79% in 2023. This indicates that the company has significantly improved its ability to generate profits before accounting for taxes and expenses over the period. The substantial growth in pretax margin suggests that Harmony Biosciences Holdings Inc has effectively managed its costs and operating expenses, leading to a healthier bottom line. Overall, the upward trajectory of the pretax margin reflects improved financial performance and efficiency in the company's operations.
Peer comparison
Dec 31, 2023